Breast cancer risk markedly lower with serum 25-hydroxyvitamin D concentrations ≥60 vs <20 ng/ml (150 vs 50 nmol/L): Pooled analysis of two randomized trials and a prospective cohort.
BACKGROUND:While numerous epidemiologic studies have found an association between higher serum 25-hydroxyvitamin D [25(OH)D] concentrations and lower breast cancer risk, few have assessed this association for concentrations >40 ng/ml. OBJECTIVE:To investigate the relationship between 25(OH)D conc...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC6003691?pdf=render |
id |
doaj-7fb283cd81f2415794b8294c03ecd9a5 |
---|---|
record_format |
Article |
spelling |
doaj-7fb283cd81f2415794b8294c03ecd9a52020-11-25T01:19:50ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01136e019926510.1371/journal.pone.0199265Breast cancer risk markedly lower with serum 25-hydroxyvitamin D concentrations ≥60 vs <20 ng/ml (150 vs 50 nmol/L): Pooled analysis of two randomized trials and a prospective cohort.Sharon L McDonnellCarole A BaggerlyChristine B FrenchLeo L BaggerlyCedric F GarlandEdward D GorhamBruce W HollisDonald L TrumpJoan M LappeBACKGROUND:While numerous epidemiologic studies have found an association between higher serum 25-hydroxyvitamin D [25(OH)D] concentrations and lower breast cancer risk, few have assessed this association for concentrations >40 ng/ml. OBJECTIVE:To investigate the relationship between 25(OH)D concentration and breast cancer risk across a broad range of 25(OH)D concentrations among women aged 55 years and older. METHODS:Analyses used pooled data from two randomized clinical trials (N = 1129, N = 2196) and a prospective cohort (N = 1713) to examine a broad range of 25(OH)D concentrations. The outcome was diagnosis of breast cancer during the observation periods (median: 4.0 years). Three analyses were conducted: 1) Incidence rates were compared according to 25(OH)D concentration from <20 to ≥60 ng/ml (<50 to ≥150 nmol/L), 2) Kaplan-Meier plots were developed and 3) multivariate Cox regression was used to examine the association between 25(OH)D and breast cancer risk using multiple 25(OH)D measurements. RESULTS:Within the pooled cohort (N = 5038), 77 women were diagnosed with breast cancer (age-adjusted incidence: 512 cases per 100,000 person-years). Results were similar for the three analyses. First, comparing incidence rates, there was an 82% lower incidence rate of breast cancer for women with 25(OH)D concentrations ≥60 vs <20 ng/ml (Rate Ratio = 0.18, P = 0.006). Second, Kaplan-Meier curves for concentrations of <20, 20-39, 40-59 and ≥60 ng/ml were significantly different (P = 0.02), with the highest proportion breast cancer-free in the ≥60 ng/ml group (99.3%) and the lowest proportion breast cancer-free in the <20 ng/ml group (96.8%). The proportion with breast cancer was 78% lower for ≥60 vs <20 ng/ml (P = 0.02). Third, multivariate Cox regression revealed that women with 25(OH)D concentrations ≥60 ng/ml had an 80% lower risk of breast cancer than women with concentrations <20 ng/ml (HR = 0.20, P = 0.03), adjusting for age, BMI, smoking status, calcium supplement intake, and study of origin. CONCLUSIONS:Higher 25(OH)D concentrations were associated with a dose-response decrease in breast cancer risk with concentrations ≥60 ng/ml being most protective.http://europepmc.org/articles/PMC6003691?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Sharon L McDonnell Carole A Baggerly Christine B French Leo L Baggerly Cedric F Garland Edward D Gorham Bruce W Hollis Donald L Trump Joan M Lappe |
spellingShingle |
Sharon L McDonnell Carole A Baggerly Christine B French Leo L Baggerly Cedric F Garland Edward D Gorham Bruce W Hollis Donald L Trump Joan M Lappe Breast cancer risk markedly lower with serum 25-hydroxyvitamin D concentrations ≥60 vs <20 ng/ml (150 vs 50 nmol/L): Pooled analysis of two randomized trials and a prospective cohort. PLoS ONE |
author_facet |
Sharon L McDonnell Carole A Baggerly Christine B French Leo L Baggerly Cedric F Garland Edward D Gorham Bruce W Hollis Donald L Trump Joan M Lappe |
author_sort |
Sharon L McDonnell |
title |
Breast cancer risk markedly lower with serum 25-hydroxyvitamin D concentrations ≥60 vs <20 ng/ml (150 vs 50 nmol/L): Pooled analysis of two randomized trials and a prospective cohort. |
title_short |
Breast cancer risk markedly lower with serum 25-hydroxyvitamin D concentrations ≥60 vs <20 ng/ml (150 vs 50 nmol/L): Pooled analysis of two randomized trials and a prospective cohort. |
title_full |
Breast cancer risk markedly lower with serum 25-hydroxyvitamin D concentrations ≥60 vs <20 ng/ml (150 vs 50 nmol/L): Pooled analysis of two randomized trials and a prospective cohort. |
title_fullStr |
Breast cancer risk markedly lower with serum 25-hydroxyvitamin D concentrations ≥60 vs <20 ng/ml (150 vs 50 nmol/L): Pooled analysis of two randomized trials and a prospective cohort. |
title_full_unstemmed |
Breast cancer risk markedly lower with serum 25-hydroxyvitamin D concentrations ≥60 vs <20 ng/ml (150 vs 50 nmol/L): Pooled analysis of two randomized trials and a prospective cohort. |
title_sort |
breast cancer risk markedly lower with serum 25-hydroxyvitamin d concentrations ≥60 vs <20 ng/ml (150 vs 50 nmol/l): pooled analysis of two randomized trials and a prospective cohort. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2018-01-01 |
description |
BACKGROUND:While numerous epidemiologic studies have found an association between higher serum 25-hydroxyvitamin D [25(OH)D] concentrations and lower breast cancer risk, few have assessed this association for concentrations >40 ng/ml. OBJECTIVE:To investigate the relationship between 25(OH)D concentration and breast cancer risk across a broad range of 25(OH)D concentrations among women aged 55 years and older. METHODS:Analyses used pooled data from two randomized clinical trials (N = 1129, N = 2196) and a prospective cohort (N = 1713) to examine a broad range of 25(OH)D concentrations. The outcome was diagnosis of breast cancer during the observation periods (median: 4.0 years). Three analyses were conducted: 1) Incidence rates were compared according to 25(OH)D concentration from <20 to ≥60 ng/ml (<50 to ≥150 nmol/L), 2) Kaplan-Meier plots were developed and 3) multivariate Cox regression was used to examine the association between 25(OH)D and breast cancer risk using multiple 25(OH)D measurements. RESULTS:Within the pooled cohort (N = 5038), 77 women were diagnosed with breast cancer (age-adjusted incidence: 512 cases per 100,000 person-years). Results were similar for the three analyses. First, comparing incidence rates, there was an 82% lower incidence rate of breast cancer for women with 25(OH)D concentrations ≥60 vs <20 ng/ml (Rate Ratio = 0.18, P = 0.006). Second, Kaplan-Meier curves for concentrations of <20, 20-39, 40-59 and ≥60 ng/ml were significantly different (P = 0.02), with the highest proportion breast cancer-free in the ≥60 ng/ml group (99.3%) and the lowest proportion breast cancer-free in the <20 ng/ml group (96.8%). The proportion with breast cancer was 78% lower for ≥60 vs <20 ng/ml (P = 0.02). Third, multivariate Cox regression revealed that women with 25(OH)D concentrations ≥60 ng/ml had an 80% lower risk of breast cancer than women with concentrations <20 ng/ml (HR = 0.20, P = 0.03), adjusting for age, BMI, smoking status, calcium supplement intake, and study of origin. CONCLUSIONS:Higher 25(OH)D concentrations were associated with a dose-response decrease in breast cancer risk with concentrations ≥60 ng/ml being most protective. |
url |
http://europepmc.org/articles/PMC6003691?pdf=render |
work_keys_str_mv |
AT sharonlmcdonnell breastcancerriskmarkedlylowerwithserum25hydroxyvitamindconcentrations60vs20ngml150vs50nmollpooledanalysisoftworandomizedtrialsandaprospectivecohort AT caroleabaggerly breastcancerriskmarkedlylowerwithserum25hydroxyvitamindconcentrations60vs20ngml150vs50nmollpooledanalysisoftworandomizedtrialsandaprospectivecohort AT christinebfrench breastcancerriskmarkedlylowerwithserum25hydroxyvitamindconcentrations60vs20ngml150vs50nmollpooledanalysisoftworandomizedtrialsandaprospectivecohort AT leolbaggerly breastcancerriskmarkedlylowerwithserum25hydroxyvitamindconcentrations60vs20ngml150vs50nmollpooledanalysisoftworandomizedtrialsandaprospectivecohort AT cedricfgarland breastcancerriskmarkedlylowerwithserum25hydroxyvitamindconcentrations60vs20ngml150vs50nmollpooledanalysisoftworandomizedtrialsandaprospectivecohort AT edwarddgorham breastcancerriskmarkedlylowerwithserum25hydroxyvitamindconcentrations60vs20ngml150vs50nmollpooledanalysisoftworandomizedtrialsandaprospectivecohort AT brucewhollis breastcancerriskmarkedlylowerwithserum25hydroxyvitamindconcentrations60vs20ngml150vs50nmollpooledanalysisoftworandomizedtrialsandaprospectivecohort AT donaldltrump breastcancerriskmarkedlylowerwithserum25hydroxyvitamindconcentrations60vs20ngml150vs50nmollpooledanalysisoftworandomizedtrialsandaprospectivecohort AT joanmlappe breastcancerriskmarkedlylowerwithserum25hydroxyvitamindconcentrations60vs20ngml150vs50nmollpooledanalysisoftworandomizedtrialsandaprospectivecohort |
_version_ |
1725137054094852096 |